AI-assisted research analysis by FutureKnowledge. Sources checked 29 October 2026. This is not investment advice.
Reviewed by FutureKnowledge: figures, dates and attributions were checked against the linked sources before publication.
Eli Lilly reported third-quarter revenue of $24.4 billion on 29 October, up 39%, and raised its 2026 sales forecast to $91 billion to $92 billion as Mounjaro and Zepbound demand kept rising. Volume, not price, did the work: prices fell sharply while the number of patients treated surged.
Eli Lilly Q3 results: the key numbers
According to Lilly’s earnings release, for the quarter ended 30 September 2026:
- Revenue: $24.40 billion, up 39% from $17.60 billion a year earlier. Year-to-date revenue reached $67.2 billion, up 46%.
- Volume and price: volume added 53 percentage points of growth while realised prices subtracted 15 points.
- Mounjaro (tirzepatide for diabetes): $10.7 billion, up 65%, of which $5.7 billion came from outside the US.
- Zepbound (tirzepatide for obesity): $5.4 billion, up 49%.
- Foundayo (oral orforglipron): $184 million in its first full quarter.
- Earnings per share: $7.22 reported, up 16%, and $7.48 on a non-GAAP basis, up 7%.
- Acquired research charges: $4.2 billion of acquired in-process R&D, equal to $4.57 per share, mainly from the AtaiBeckley and Curevo deals.
The release says the quarter also included roughly $900 million of one-time benefits, including $410 million of Jardiance milestone payments, which flatters the headline growth rate somewhat. TradingView’s summary of the results puts operating income at $8.61 billion, up 17%, and net income at $6.45 billion, up 16%.
How Lilly’s results compared with expectations
Analysts had expected revenue of about $22.61 billion and adjusted EPS of $6.61, so Lilly beat by 7.9% and 13.2% respectively, StockStory reported. It recorded the shares rising 4.2% to about $1,343 immediately after the report; the move later in the US session may differ.
The one product that fell short was Foundayo. Grafa reported that analysts had looked for about $234 million against the $184 million delivered. Because the oral pill is the company’s bet on a cheaper, easier-to-manufacture obesity treatment, its early launch curve will be watched closely in coming quarters.
Chief executive Dave Ricks said in the release that Lilly had “another strong quarter, exceeding our prior expectations.”
Why revenue rose while prices fell
The split between volume and price is the most important detail in the Lilly results. In the US, revenue rose 34% on 41% higher volume and 7% lower prices. Outside the US, revenue rose 47%, with volume up 76% and prices down 29%. The release attributes most of the international price drop to Mounjaro’s inclusion in China’s National Reimbursement Drug List (NRDL), which typically trades a lower price for much wider access.
The pattern is the business model of the obesity-drug market in 2026: lower list and net prices, broader insurance and government coverage, and much larger patient numbers. As long as volume grows faster than price falls, revenue keeps rising. Lilly’s gross margin rose to 83.9% of revenue, up one percentage point, suggesting that manufacturing scale is absorbing the lower prices for now.
Guidance: higher sales, lower EPS range
Lilly raised its 2026 outlook as follows, per the release:
- Revenue: $91 billion to $92 billion, from $85 billion to $87 billion. StockStory said the $91.5 billion midpoint was 3.3% above consensus.
- Performance margin: 52.0% to 52.5%, from 49.0% to 50.5%.
- Non-GAAP EPS: $35.00 to $36.00, from $35.50 to $36.50.
The lower EPS range looks like a cut but is driven by deal accounting. Lilly says the underlying business added $4.07 to the midpoint, more than offset by the $4.57 per share acquired R&D charge booked in the third quarter. The guidance excludes any such charges after 30 September, so further acquisitions would lower reported EPS again.
Pipeline and the rivalry with Novo Nordisk
Lilly also used the quarter to strengthen its pipeline. The release says retatrutide beat Novo Nordisk’s Ozempic 2 mg in a head-to-head Phase 3 trial in type 2 diabetes, on both weight loss and blood-sugar control, and that a combination of eloralintide and tirzepatide outperformed tirzepatide alone, with Phase 3 trials planned to start in the fourth quarter. Regulators approved several products in September and October, including Onswik, a once-weekly basal insulin, and a cardiovascular-risk indication for Mounjaro.
For the wider pharmaceutical sector, Lilly’s scale is now a benchmark. FutureKnowledge’s report on Novartis raising its 2026 outlook showed how peers are relying on a broader mix of drugs for growth.
What it means for India and businesses
The direct link to India is through generic and contract manufacturers. Price cuts and NRDL-style volume deals point to an obesity and diabetes market that is getting bigger but cheaper per patient, which favours low-cost, high-volume manufacturing. Indian drugmakers that depend on US generics, as the recent fall in Cipla’s US sales showed, are looking for new growth areas, and the GLP-1 class is one of them. Lilly gave no India-specific figures in its release.
Who is more or less exposed
- More exposed to Lilly’s growth: suppliers of injector pens, active ingredients and fill-finish capacity, and contractors building the new US plants where Lilly held groundbreakings in Houston and Richmond during the quarter.
- More exposed to price pressure: rival obesity-drug makers whose volumes are growing more slowly than prices are falling.
- Mixed: insurers and governments, which pay less per patient but cover far more patients.
Scenarios to watch (conditional scenarios, not predictions)
| If… | Then a plausible outcome is… |
|---|---|
| Volume keeps growing faster than prices fall | Revenue growth could stay strong even as per-patient prices decline |
| Foundayo’s launch stays below expectations | Investors may question how quickly the oral pill can broaden the market |
| Lilly makes further large acquisitions | Reported EPS guidance could fall again because of acquired R&D charges |
| More countries add tirzepatide to reimbursement lists | International volume could rise further with lower realised prices |
What to watch next
- Lilly’s 10-Q filing for detail on pricing and the one-time benefits.
- Foundayo prescription trends in the next two quarters.
- Start of Phase 3 trials for the eloralintide combination in the fourth quarter.
- Novo Nordisk’s next results, for a read on how the two leaders are dividing the market.
Bottom line
Eli Lilly’s Q3 results show an obesity and diabetes franchise growing on volume despite falling prices, with Mounjaro alone near $11 billion a quarter. The higher revenue forecast is the main signal; the lower EPS range reflects deal charges rather than weaker operations, while a slower start for the Foundayo pill is the main soft spot.
Method note: This analysis compared Lilly’s third-quarter 2026 earnings release on PR Newswire (primary source) with reporting by StockStory, Grafa and TradingView. Analyst estimates are from StockStory (revenue, EPS, guidance) and Grafa (Foundayo); the share move is StockStory’s immediate post-release figure.